Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 7/20 | 0.59 |
| ▸ | PPARG | P37231 | 5/20 | 0.59 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | LPL | P06858 | 2/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.49 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19542672 | 0.88 | PPARA (0.52) | PPARAPPARGLPLLIPGKAT8 | |
| SCHEMBL289200 | 0.85 | PPARA (0.53) | PPARAPPARGLPLLIPG | |
| SCHEMBL290046 | 0.84 | PPARA (0.52) | PPARAPPARGCYP4F2CYP4A11LPL | |
| SCHEMBL17672780 | 0.84 | GPR84 (0.54) | PPARAPPARGKAT8ALDH1A1 | |
| SCHEMBL129672 | 0.84 | CYP2C19 (0.53) | CYP4F2CYP4A11CYP1A2CYP2C19 | |
| SCHEMBL20160762 | 0.82 | PPARA (0.50) | PPARAPPARGCYP4F2CYP4A11LPL | |
| SCHEMBL1051632 | 0.81 | ALDH1A1 (0.59) | CYP1A2ALDH1A1 | |
| SCHEMBL6280362 | 0.79 | LPL (0.54) | PPARAPPARGLPLLIPG | |
| SCHEMBL5617436 | 0.78 | SCN5A (0.52) | PPARAPPARGLPLLIPGKAT8 | |
| SCHEMBL1124987 | 0.78 | CYP2C19 (0.50) | CYP4F2CYP4A11CYP1A2CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11267779-B2 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | PROMETIC PHARMA SMT LIMITED (GB) | 2022-03-08 | — | — | US | disclosed |
| CN-107106526-B | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration | 普罗米蒂克医药SMT有限公司 | 2021-05-28 | — | — | CN | disclosed |
| US-20210085626-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION | LIMINAL BIOSCIENCES LTD (GB) | 2021-03-25 | — | — | US | disclosed |
| US-20210085626-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION | LIMINAL BIOSCIENCES LTD (GB) | 2021-03-25 | — | — | US | disclosed |
| US-20210002202-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses Thereof | PROMETIC BIOSCIENCES, INC. (CA) | 2021-01-07 | — | — | US | disclosed |
| US-20210002202-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses Thereof | PROMETIC BIOSCIENCES, INC. (CA) | 2021-01-07 | — | — | US | disclosed |
| US-10869849-B2 | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration | Liminal Biosciences Limited (GB) | 2020-12-22 | — | — | US | disclosed |
| US-10869849-B2 | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration | Liminal Biosciences Limited (GB) | 2020-12-22 | — | — | US | disclosed |
| US-10815183-B2 | Substituted aromatic compounds and pharmaceutical uses thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2020-10-27 | — | — | US | disclosed |
| US-10815183-B2 | Substituted aromatic compounds and pharmaceutical uses thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2020-10-27 | — | — | US | disclosed |
| US-8927765-B2 | Substituted aromatic compounds and pharmaceutical uses thereof | PROMETIC BIOSCIENCES INC. (CA) | 2015-01-06 | — | — | US | disclosed |
| US-8927765-B2 | Substituted aromatic compounds and pharmaceutical uses thereof | PROMETIC BIOSCIENCES INC. (CA) | 2015-01-06 | — | — | US | disclosed |
| WO-2014138907-A1 | SUBSTITUTED AROMATIC COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, LIVER FIBROSIS, SKIN FIBROSIS AND CARDIAC FIBROSIS | PROMETIC BIOSCIENCES INC. (CA) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014138907-A1 | SUBSTITUTED AROMATIC COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, LIVER FIBROSIS, SKIN FIBROSIS AND CARDIAC FIBROSIS | PROMETIC BIOSCIENCES INC. (CA) | 2014-09-18 | — | — | WO | disclosed |
| US-20120088784-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2012-04-12 | — | — | US | disclosed |
| US-20120088784-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2012-04-12 | — | — | US | disclosed |
| US-20120088784-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2012-04-12 | — | — | US | disclosed |
| EP-2427416-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | ProMetic BioSciences Inc. (CA) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010127440-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | PROMETIC BIOSCIENCES INC. (CA) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010127440-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | PROMETIC BIOSCIENCES INC. (CA) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210085626-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION | COL1A1, CCNH, COL2A1 | PPARA 2564/4885PPARG 958/4885CYP4F2 289/4885 |
| US-10815183-B2 | Substituted aromatic compounds and pharmaceutical uses thereof | TYR, PAH, REN | PPARA 276/4885PPARG 212/4885CYP4F2 74/4885 |
| US-20210002202-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses Thereof | TYR, PAH, REN | PPARA 276/4885PPARG 212/4885CYP4F2 74/4885 |
| US-10869849-B2 | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration | COL1A1, CCNH, COL2A1 | PPARA 2564/4885PPARG 958/4885CYP4F2 289/4885 |
| US-20120088784-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses thereof | TYR, PAH, REN | PPARA 276/4885PPARG 212/4885CYP4F2 74/4885 |
| US-11267779-B2 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | PAH, HRH3, CFH | PPARA 3243/4885PPARG 2346/4885CYP4F2 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.